Abstract: A signal control system is capable of acquiring an image of a road from a camera disposed around a road in a control target area and includes a passability determination part for determining passability of a road section starting from an intersection on a basis of an abnormality in an image photographed by the camera and a signal control part for controlling a traffic signal device disposed at an intersection included in the road section so as to prevent traffic from inflowing into a closed section.

Abstract: An evacuation route guidance system, which can respectively acquire one or more images shot by one or more cameras placed near roads of a target area, and a hazard map which includes locations of one or more dangerous places and locations of one or more safe areas in the target aera, including: a movement analysis part for analyzing movement of one or more moving bodies passing through a road in the target area based on one or more images shot by the one or more cameras at a time of occurrence of a disaster; a route creation part for creating a route adapted to movement of a moving body passing through the road, which route enables the moving body to move to a safe area by avoiding the one or more dangerous places; and a route output part for outputting the route to a predetermined display apparatus.

Abstract: The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. Our findings suggested that elevated LAT1 expression in PC is a novel biomarker for high-grade malignancy. Independently of GS, aberrant LAT1 overexpression might be used to screen for aggressive phenotypes of PC that should be treated medically. Prostate biopsies are usually small samples, limiting the evaluation of the tumor area. Thus, LAT1 intensity in prostate biopsy samples may be more a reliable prognostic marker of LP. Especially, we propose LAT1 evaluation against PC with low-risk patients in order to screen who can receive active surveillance. Several LAT1 inhibitors have been found to suppress cancer cell proliferation, so inhibition of LAT1 may be a potential therapeutic strategy for PC and other human cancers.

Abstract: The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. Our findings suggested that elevated LAT1 expression in PC is a novel biomarker for high-grade malignancy. Independently of GS, aberrant LAT1 overexpression might be used to screen for aggressive phenotypes of PC that should be treated medically. Prostate biopsies are usually small samples, limiting the evaluation of the tumor area. Thus, LAT1 intensity in prostate biopsy samples may be more a reliable prognostic marker of LP. Especially, we propose LAT1 evaluation against PC with low-risk patients in order to screen who can receive active surveillance. Several LAT1 inhibitors have been found to suppress cancer cell proliferation, so inhibition of LAT1 may be a potential therapeutic strategy for PC and other human cancers.